Effects of Association Between Resveratrol and Ketamine on Behavioral and Biochemical Analysis in Mice

Overview

Journal J Neural Transm (Vienna)

Specialties Neurology
Physiology

Date 2024 Jun 14

PMID 38874765

Authors

Patricia Zorzi Juliani

Talita Rodrigues

Getulio Nicola Bressan

Camila Camponogara

Sara Marchesan Oliveira

Natalia Brucker

Roselei Fachinetto

Affiliations

Soon will be listed here.

Abstract

Resveratrol (3,5,4'-trihydroxy-trans-stilbene), a phenol commonly found in grapes and wine, has been associated as protective in experimental models involving alterations in different neurotransmitter systems. However, studies are reporting that resveratrol could have adverse effects. This study evaluated if the association of a low dose of ketamine and resveratrol could induce behavioral manifestations associated with biochemical alterations. Moreover, the effects of treatment with resveratrol and/or ketamine on monoamine oxidase (MAO) activity, oxidative stress markers, and IL-6 levels in the brain were also investigated. Male Swiss mice received a low dose of ketamine (20 mg/kg) for 14 consecutive days, and resveratrol (10, 30, or 100 mg/kg) from day 8 up to day 14 of the experimental period, intraperitoneally. Locomotor, stereotyped behavior, Y-maze, novel recognition object test (NORT), and social interaction were quantified as well as ex vivo analysis of MAO activity, IL-6 levels, and oxidative stress markers (TBARS and total thiol levels) in brain tissues. Ketamine per se reduced the number of bouts of stereotyped behavior on day 8 of the experimental period. Resveratrol per se reduced the locomotor and exploratory activity in the open field, the time of exploration of new objects in the NORT, MAO-A activity in the striatum and increased the IL-6 levels in the cortex. These effects were attenuated when the mice were co-treated with ketamine and resveratrol. There was a decrease in MAO-A activity in the cortex of mice treated with ketamine + resveratrol 100 mg/kg. No significant alterations were found in oxidative stress markers. Resveratrol does not appear to cause summative effects with ketamine on behavioral alterations. However, the effect of resveratrol per se, mainly on locomotor and exploratory activity, should be better investigated.

Citing Articles

Resveratrol: A Multifaceted Guardian against Anxiety and Stress Disorders-An Overview of Experimental Evidence.

Tseilikman V, Tseilikman O, Yegorov O, Brichagina A, Karpenko M, Tseilikman D Nutrients. 2024; 16(17).

PMID: 39275174 PMC: 11396965. DOI: 10.3390/nu16172856.

References

Ahmad S, Ansari M, Nadeem A, Bakheet S, Alzahrani M, Alshammari M . Resveratrol attenuates pro-inflammatory cytokines and activation of JAK1-STAT3 in BTBR T Itpr3/J autistic mice. Eur J Pharmacol. 2018; 829:70-78. DOI: 10.1016/j.ejphar.2018.04.008. View

Bastianetto S, Menard C, Quirion R . Neuroprotective action of resveratrol. Biochim Biophys Acta. 2014; 1852(6):1195-201. DOI: 10.1016/j.bbadis.2014.09.011. View

Ben-Azu B, Aderibigbe A, Ajayi A, Eneni A, Umukoro S, Iwalewa E . Involvement of GABAergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice. Brain Res Bull. 2018; 139:292-306. DOI: 10.1016/j.brainresbull.2018.03.006. View

Ben-Azu B, Uruaka C, Ajayi A, Jarikre T, Nwangwa K, Chilaka K . Reversal and Preventive Pleiotropic Mechanisms Involved in the Antipsychotic-Like Effect of Taurine, an Essential β-Amino Acid in Ketamine-Induced Experimental Schizophrenia in Mice. Neurochem Res. 2022; 48(3):816-829. DOI: 10.1007/s11064-022-03808-5. View

Busanello A, Barbosa N, Peroza L, Farias L, Burger M, Barreto K . Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice. Behav Pharmacol. 2010; 22(1):71-5. DOI: 10.1097/FBP.0b013e328341e9b4. View

Busanello A, Peroza L, Wagner C, Sudati J, Pereira R, de S Prestes A . Resveratrol reduces vacuous chewing movements induced by acute treatment with fluphenazine. Pharmacol Biochem Behav. 2012; 101(2):307-10. DOI: 10.1016/j.pbb.2012.01.007. View

Calleri E, Pochetti G, Dossou K, Laghezza A, Montanari R, Capelli D . Resveratrol and its metabolites bind to PPARs. Chembiochem. 2014; 15(8):1154-1160. PMC: 4104805. DOI: 10.1002/cbic.201300754. View

Carradori S, Fantacuzzi M, Ammazzalorso A, Angeli A, De Filippis B, Galati S . Resveratrol Analogues as Dual Inhibitors of Monoamine Oxidase B and Carbonic Anhydrase VII: A New Multi-Target Combination for Neurodegenerative Diseases?. Molecules. 2022; 27(22). PMC: 9694798. DOI: 10.3390/molecules27227816. View

10.

Chiapinotto Ceretta A, Schaffer L, de Freitas C, Reinheimer J, Dotto M, Fachinetto R . Gabapentin prevents behavioral changes on the amphetamine-induced animal model of schizophrenia. Schizophr Res. 2016; 175(1-3):230-231. DOI: 10.1016/j.schres.2016.04.044. View

11.

Chiapinotto Ceretta A, de Freitas C, Schaffer L, Reinheimer J, Dotto M, de Moraes Reis E . Gabapentin reduces haloperidol-induced vacuous chewing movements in mice. Pharmacol Biochem Behav. 2018; 166:21-26. DOI: 10.1016/j.pbb.2018.01.003. View

12.

Chamoli M, Chinta S, Andersen J . An inducible MAO-B mouse model of Parkinson's disease: a tool towards better understanding basic disease mechanisms and developing novel therapeutics. J Neural Transm (Vienna). 2018; 125(11):1651-1658. DOI: 10.1007/s00702-018-1887-z. View

13.

Cheng W, Chen C, Chen C, Huang M, Pietrzak R, Krystal J . Similar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia. Schizophr Res. 2018; 199:313-318. DOI: 10.1016/j.schres.2018.02.049. View

14.

Di Liberto V, Makela J, Korhonen L, Olivieri M, Tselykh T, Malkia A . Involvement of estrogen receptors in the resveratrol-mediated increase in dopamine transporter in human dopaminergic neurons and in striatum of female mice. Neuropharmacology. 2011; 62(2):1011-8. DOI: 10.1016/j.neuropharm.2011.10.010. View

15.

Fachinetto R, Villarinho J, Wagner C, Pereira R, Avila D, Burger M . Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(7):1478-86. DOI: 10.1016/j.pnpbp.2007.06.028. View

16.

Fantacuzzi M, Amoroso R, Carradori S, De Filippis B . Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy. Eur J Med Chem. 2022; 233:114242. DOI: 10.1016/j.ejmech.2022.114242. View

17.

Farkhakfar A, Hassanpour S, Zendehdel M . Resveratrol plays neuroprotective role on ketamine-induced schizophrenia-like behaviors and oxidative damage in mice. Neurosci Lett. 2023; 813:137436. DOI: 10.1016/j.neulet.2023.137436. View

18.

Figueira F, Leal C, de Moraes Reis E, Ropke J, Wagner C, da Rocha J . Effects of diphenyl diselenide on behavioral and biochemical changes induced by amphetamine in mice. J Neural Transm (Vienna). 2014; 122(2):201-9. DOI: 10.1007/s00702-014-1257-4. View

19.

Finberg J . Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther. 2014; 143(2):133-52. DOI: 10.1016/j.pharmthera.2014.02.010. View

20.

Hann Yih T, Abd Ghapor A, Agarwal R, Razali N, Iezhitsa I, Ismail N . Effect of trans-resveratrol on glutamate clearance and visual behaviour in rats with glutamate induced retinal injury. Exp Eye Res. 2022; 220:109104. DOI: 10.1016/j.exer.2022.109104. View

21.

Hsieh C, Chang W, Chen L, Chen H, Chan M . Differential inhibitory effects of resveratrol on excitotoxicity and synaptic plasticity: involvement of NMDA receptor subtypes. Nutr Neurosci. 2019; 24(6):443-458. DOI: 10.1080/1028415X.2019.1641995. View